Novavax issues 2025 financial guidance and strategic update at TD Cowen conference

NOVAVAX INC

Provided 2025 revenue framework and combined R&D/SG&A expense guidance for 2025 and 2026.
Reaffirmed transition of COVID-19 vaccine commercialization to Sanofi starting 2025-2026 season.
Highlighted clinical progress on COVID-19, CIC, and standalone flu vaccine candidates.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.